PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.44%
EBIT growth 50-75% of AXSM's 23.84%. Martin Whitman would suspect suboptimal resource allocation.
14.44%
Operating income growth under 50% of AXSM's 35.57%. Michael Burry would be concerned about deeper cost or sales issues.
12.51%
Net income growth at 50-75% of AXSM's 19.26%. Martin Whitman would question fundamental disadvantages in expenses or demand.
12.37%
EPS growth at 50-75% of AXSM's 20.49%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
12.37%
Diluted EPS growth at 50-75% of AXSM's 20.49%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.24%
OCF growth under 50% of AXSM's 25.25%. Michael Burry might suspect questionable revenue recognition or rising costs.
1.24%
FCF growth under 50% of AXSM's 25.25%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.48%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-6.48%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-6.48%
Negative 3Y OCF/share CAGR while AXSM stands at 23.58%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-180.68%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-180.68%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-180.68%
Negative 3Y CAGR while AXSM is 11.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-183.69%
Negative equity/share CAGR over 10 years while AXSM stands at 360.64%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-183.69%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-183.69%
Negative 3Y equity/share growth while AXSM is at 280.02%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.05%
Negative asset growth while AXSM invests at 7.23%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-17.69%
We have a declining book value while AXSM shows 35.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
7.69%
Debt growth far above AXSM's 2.81%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
175.10%
SG&A growth well above AXSM's 7.86%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.